45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
2,646
Insurances with rates
31
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| RX-244996 | EFGARTIGIMOD ALFA 1008 MG-HYALURON-QVFC 11,200 UNIT/5.6 ML SUBCUT SOLN | $60,344 | $39,223 | — | — | 90 |
| 093 | OTHER DISORDERS OF NERVOUS SYSTEM WITHOUT CC/MCC | $48,536 | $31,548 | — | — | 79 |
| CASE-36593 | Declot Thrombolytic of Vad | $47,302 | $30,747 | — | — | 63 |
| RX-231925 | LUSPATERCEPT-AAMT 75 MG SUBCUTANEOUS SOLUTION|RX AMT DISCARD/NOT ADMIN TO PT | $45,365 | $29,487 | — | — | 90 |
| RX-191027 | CABAZITAXEL 10 MG/ML (FIRST DILUTION) INTRAVENOUS SOLUTION | $42,527 | $27,643 | — | — | 89 |
| RX-218713 | ATEZOLIZUMAB 1,200 MG/20 ML (60 MG/ML) INTRAVENOUS SOLUTION | $42,206 | $27,434 | — | — | 90 |
| RX-227274 | CEMIPLIMAB-RWLC 50 MG/ML INTRAVENOUS SOLUTION|RX AMT DISCARD/NOT ADMIN TO PT | $39,775 | $25,854 | — | — | 90 |
| RX-233531 | DARATUMUMAB 1,800 MG-HYALURONIDASE-FIHJ 30,000 UNIT/15 ML SUBCUT SOLN | $39,657 | $25,777 | — | — | 90 |
| 643 | ENDOCRINE DISORDERS WITH MCC | $34,199 | $22,230 | — | — | 79 |
| RX-194025 | IPILIMUMAB 50 MG/10 ML (5 MG/ML) INTRAVENOUS SOLUTION | $33,302 | $21,646 | — | — | 90 |
| 177 | RESPIRATORY INFECTIONS AND INFLAMMATIONS WITH MCC | $32,315 | $21,005 | — | — | 79 |
| RX-207710 | OBINUTUZUMAB 1,000 MG/40 ML INTRAVENOUS SOLUTION | $32,310 | $21,001 | — | — | 90 |
| 640 | MISCELLANEOUS DISORDERS OF NUTRITION, METABOLISM, FLUIDS AND ELECTROLYTES WITH MCC | $31,449 | $20,442 | — | — | 79 |
| RX-233784 | LURBINECTEDIN 4 MG INTRAVENOUS SOLUTION | $30,425 | $19,776 | — | — | 89 |
| 605 | TRAUMA TO THE SKIN, SUBCUTANEOUS TISSUE AND BREAST WITHOUT MCC | $29,806 | $19,374 | — | — | 79 |
| RX-229308 | ATEZOLIZUMAB 840 MG/14 ML (60 MG/ML) INTRAVENOUS SOLUTION|RX AMT DISCARD/NOT ADMIN TO PT | $29,536 | $19,198 | — | — | 90 |
| RX-224645 | NIVOLUMAB 240 MG/24 ML INTRAVENOUS SOLUTION | $29,214 | $18,989 | — | — | 90 |
| 178 | RESPIRATORY INFECTIONS AND INFLAMMATIONS WITH CC | $28,678 | $18,641 | — | — | 79 |
| RX-209334 | RAMUCIRUMAB 10 MG/ML INTRAVENOUS SOLUTION|RX AMT DISCARD/NOT ADMIN TO PT | $27,588 | $17,932 | — | — | 89 |
| RX-179915 | PANITUMUMAB 400 MG/20 ML (20 MG/ML) INTRAVENOUS SOLUTION | $27,187 | $17,671 | — | — | 90 |
| RX-79826 | ALTEPLASE 100 MG INTRAVENOUS SOLUTION | $26,401 | $17,161 | — | — | 90 |
| RX-213469 | OCTREOTIDE,MICROSPHERES ER 30 MG INTRAMUSCULAR SUSP, EXTENDED RELEASE | $25,934 | $16,857 | — | — | 90 |
| RX-200555 | PERTUZUMAB 420 MG/14 ML (30 MG/ML) INTRAVENOUS SOLUTION | $25,589 | $16,633 | — | — | 90 |
| 372 | MAJOR GASTROINTESTINAL DISORDERS AND PERITONEAL INFECTIONS WITH CC | $25,421 | $16,524 | — | — | 79 |
| 555 | SIGNS AND SYMPTOMS OF MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITH MCC | $25,023 | $16,265 | — | — | 79 |
| RX-254199 | TENECTEPLASE 25 MG INTRAVENOUS SOLUTION | $24,892 | $16,180 | — | — | 89 |
| RX-225219 | TENECTEPLASE 50 MG INTRAVENOUS SOLUTION | $24,892 | $16,180 | — | — | 89 |
| RX-243179 | MIRVETUXIMAB SORAVTANSINE-GYNX 5 MG/ML INTRAVENOUS SOLUTION | $24,886 | $16,176 | — | — | 89 |
| 280 | ACUTE MYOCARDIAL INFARCTION, DISCHARGED ALIVE WITH MCC | $23,757 | $15,442 | — | — | 79 |
| 439 | DISORDERS OF PANCREAS EXCEPT MALIGNANCY WITH CC | $23,137 | $15,039 | — | — | 79 |
| 391 | ESOPHAGITIS, GASTROENTERITIS AND MISCELLANEOUS DIGESTIVE DISORDERS WITH MCC | $23,061 | $14,990 | — | — | 79 |
| RX-213967 | IMMUNE GLOB,GAMM(IGG) 10 %-PRO-IGA 0 TO 50 MCG/ML INTRAVENOUS SOLUTION | $22,594 | $14,686 | — | — | 356 |
| RX-212708 | PEMBROLIZUMAB 25 MG/ML INTRAVENOUS SOLUTION|RX AMT DISCARD/NOT ADMIN TO PT | $22,116 | $14,376 | — | — | 90 |
| 309 | CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH CC | $21,906 | $14,239 | — | — | 77 |
| 948 | SIGNS AND SYMPTOMS WITHOUT MCC | $21,575 | $14,024 | — | — | 79 |
| 861 | SIGNS, SYMPTOMS AND OTHER FACTORS INFLUENCING HEALTH STATUS,MODERATE | $21,575 | — | — | — | 1 |
| 862 | POSTOPERATIVE AND POST-TRAUMATIC INFECTIONS WITH MCC | $21,398 | $13,909 | — | — | 79 |
| 463 | KIDNEY AND URINARY TRACT INFECTIONS,MAJOR | $20,994 | — | — | — | 1 |
| 871 | SEPTICEMIA OR SEVERE SEPSIS WITHOUT MV >96 HOURS WITH MCC | $20,944 | $13,613 | — | — | 79 |
| 371 | MAJOR GASTROINTESTINAL DISORDERS AND PERITONEAL INFECTIONS WITH MCC | $20,599 | $13,389 | — | — | 79 |
| 189 | PULMONARY EDEMA AND RESPIRATORY FAILURE | $20,165 | $13,107 | — | — | 79 |
| 312 | SYNCOPE AND COLLAPSE | $19,614 | $12,749 | — | — | 79 |
| 179 | RESPIRATORY INFECTIONS AND INFLAMMATIONS WITHOUT CC/MCC | $19,389 | $12,603 | — | — | 79 |
| RX-83055 | PEGFILGRASTIM 6 MG/0.6 ML SUBCUTANEOUS SYRINGE | $19,254 | $12,515 | — | — | 90 |
| RX-212539 | PEGFILGRASTIM 6 MG/0.6 ML (DELIVERABLE) WEARABLE SUBCUTANEOUS INJECTOR | $19,254 | $12,515 | — | — | 90 |
| 466 | MALFUNCTION, REACTION, COMPLICATION OF GENITOURINARY DEVICE OR PROCEDURE,MAJOR | $19,118 | — | — | — | 1 |
| 698 | OTHER KIDNEY AND URINARY TRACT DIAGNOSES WITH MCC | $19,118 | $12,427 | — | — | 79 |
| 202 | BRONCHITIS AND ASTHMA WITH CC/MCC | $18,981 | $12,338 | — | — | 79 |
| 308 | CARDIAC ARRHYTHMIA AND CONDUCTION DISORDERS WITH MCC | $18,976 | $12,334 | — | — | 79 |
| 194 | SIMPLE PNEUMONIA AND PLEURISY WITH CC | $18,041 | $11,727 | — | — | 79 |
Showing top 50 of 2,646 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.